Halozyme Therapeutics, Inc. HALO
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 485.42M | 413.60M | 348.84M | 316.89M | 595.49M |
| Total Depreciation and Amortization | 128.58M | 114.80M | 101.34M | 88.05M | 81.79M |
| Total Amortization of Deferred Charges | 8.67M | 8.31M | 7.91M | 7.51M | 7.40M |
| Total Other Non-Cash Items | 391.83M | 419.36M | 405.26M | 391.37M | 43.78M |
| Change in Net Operating Assets | -116.23M | -137.47M | -185.93M | -152.26M | -117.46M |
| Cash from Operations | 898.27M | 818.60M | 677.42M | 651.56M | 611.00M |
| Capital Expenditure | -12.39M | -12.37M | -9.76M | -6.97M | -8.60M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -725.26M | -725.26M | -725.26M | -725.97M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -48.73M | 131.91M | 276.75M | 187.12M | 234.05M |
| Cash from Investing | -786.38M | -605.72M | -458.27M | -545.81M | 225.46M |
| Total Debt Issued | 2.94B | 1.47B | 1.47B | 1.47B | -- |
| Total Debt Repaid | -1.67B | -1.01B | -1.01B | -1.01B | -- |
| Issuance of Common Stock | 31.81M | 25.49M | 21.83M | 21.83M | 21.27M |
| Repurchase of Common Stock | -400.00M | -371.61M | -340.66M | -342.37M | -592.37M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -409.21M | -221.24M | -221.24M | -221.24M | -- |
| Cash from Financing | 499.30M | -110.75M | -83.47M | -85.17M | -571.10M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 611.18M | 102.13M | 135.68M | 20.57M | 265.35M |